Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Lion Biotechnologies Inc (LBIO): Ayer Capital Management Halves Its Stake

Biotech stocks have been in the middle of everyone’s attention lately and many have gained impressive ground (often not justified by the company’s lack of revenue and huge losses). In this way, some investors are picking profits, such as Jay Venkatesen‘s Ayer Capital Management, which has sold 2.78 million shares of Lion Biotechnologies Inc (NASDAQ:LBIO) and slashed its stake to 2.82 million shares, representing around 6.30% of the company’s outstanding stock. As Ayer disclosed in the filing, it sold the shares in one transaction at $9.63 per unit.


Ayer’s transaction was a part of an underwritten secondary offering that involved $4.75 million shares of Lion Biotechnologies Inc (NASDAQ:LBIO) with a 0.375 gross spread to the underwriters. The securities were sold only by stockholders, including members of the board, while Lion Biotechnologies has not disposed of any shares and therefore has not received any proceeds.

Lion Biotechnologies Inc (NASDAQ:LBIO) is a $484 million development-stage biotechnology company, whose stock surged by 36% since the beginning of the year. It represented the largest position in Ayer Capital’s equity portfolio at the end of March, the only other holding being a 250,000 shares in Oncothyreon Inc (USA) (NASDAQ:ONTY), a clinical-stage biopharmaceutical company, whose stock is up by 25% year-to-date.

Other shareholders of Lion Biotechnologies Inc (NASDAQ:LBIO) include Daniel Gold’s QVT Financial and Baker Bros. Advisors, which initiated stakes with 1.33 million shares each during the first quarter. Kevin Kotler‘s Broadfin Capital also disclosed a new position with 1.06 million shares in its latest 13F filing.

Disclosure: none

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.